Isolation and Characterization of an Adventitious Avian Leukosis Virus Isolated from Commercial Marek's Disease Vaccines

Abstract Commercial Marek's disease (MD) vaccines produced by two manufacturers were tested for possible contamination with avian leukosis virus (ALV). Samples of MD vaccines manufactured by two companies (A and B) were received from a breeder company; samples were also received directly from vaccine company B. Using virus isolation tests, samples initially tested positive for subgroup E (endogenous) ALV. However, upon repassage, the vaccines also tested positive for exogenous ALV. The isolated exogenous ALV proved to be a subgroup A virus, as determined by flow cytometry using polyclonal chicken antibodies specific for various subgroups of ALV, and by DNA sequencing of the envelope glygoprotein (gp85). The exogenous ALV isolated from MD vaccines was inoculated in chickens from ADOL lines 15I5 × 71 and 0 to determine its pathogenicity and compare it with that of Rous-associated-virus–1 (RAV-1), the prototype strain of ALV-A. Each chicken from each line was inoculated with approximately 10,000 infectious units of RAV-1 or the ALV-A isolated from vaccines termed B-39 virus at 7th day of embryonation. At hatch, and at 4, 8, and 16 wk of age, chickens were tested for viremia and cloacal shedding; chickens were also observed for ALV-induced tumors within 16 wk of age. Viremia and cloacal shedding results suggest that chickens from both lines were susceptible to infection with either virus. Within 16 wk of age, the proportion of ALV tumors induced by strain B-39 in line 0 and line 15I5 × 71 chickens was 0% and 12%, respectively, compared with 62% and 67% in chickens inoculated with RAV-1. The data indicate that commercial MD vaccines produced by two manufacturers were contaminated with endogenous subgroup E and an exogenous subgroup A ALV. Further, data from biological characterization suggest that the ALV-A isolated from commercial MD vaccines is of low oncogenicity, compared with that of RAV-1. GenBank accession numbers: The gp85 gene sequences of ALV isolated from commercial Marek's disease vaccines have been deposited in GenBank and assigned the following accession numbers: A46 subgroup A, DQ412726 ; B53 subgroup A, DQ412727; A46 subgroup E, DQ412728; B53 subgroup E, DQ412729.

[1]  Kanji Hirai,et al.  Marek’s Disease , 2001, Current Topics in Microbiology and Immunology.

[2]  W. Heneine,et al.  Lack of evidence of endogenous avian leukosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients. , 2001, Emerging infectious diseases.

[3]  H. Hunt,et al.  Identification and characterization of recombinant subgroup J avian leukosis viruses (ALV) expressing subgroup A ALV envelope. , 2000, Virology.

[4]  H. Hunt,et al.  Hypervariability in the envelope genes of subgroup J avian leukosis viruses obtained from different farms in the United States. , 2000, Virology.

[5]  H. Hunt,et al.  A genetically engineered cell line resistant to subgroup J avian leukosis virus infection (C/J). , 1999, Virology.

[6]  W. Heneine,et al.  Evidence of Avian Leukosis Virus Subgroup E and Endogenous Avian Virus in Measles and Mumps Vaccines Derived from Chicken Cells: Investigation of Transmission to Vaccine Recipients , 1999, Journal of Virology.

[7]  L. N. Payne.  Leukosis/sarcoma group , 1997 .

[8]  E. Smith,et al.  An outbreak of lymphomas in commercial broiler breeder chickens vaccinated with a fowlpox vaccine contaminated with reticuloendotheliosis virus. , 1996, Avian pathology : journal of the W.V.P.A.

[9]  H. Nagai,et al.  Detection of contamination of vaccines with the reticuloendotheliosis virus by reverse transcriptase polymerase chain reaction (RT-PCR). , 1996, Virus research.

[10]  I. Reimann,et al.  Use of the polymerase chain reaction for the detection of reticuloendotheliosis virus in Marek's disease vaccines and chicken tissues. , 1996, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B.

[11]  G. F. de Boer,et al.  Avian lymphoid leukosis: mechanisms of lymphomagenesis. , 1988, Advances in veterinary science and comparative medicine.

[12]  S. McMahon,et al.  Embryonic infection with the endogenous avian leukosis virus Rous-associated virus-0 alters responses to exogenous avian leukosis virus infection , 1987, Journal of virology.

[13]  E. Smith,et al.  A comparison of test materials for differentiating avian leukosis virus group-specific antigens of exogenous and endogenous origin. , 1984, Avian diseases.

[14]  E. Smith,et al.  An enzyme-linked immunosorbent assay for detecting avian leukosis-sarcoma viruses. , 1979, Avian diseases.

[15]  S. E. Dunn,et al.  Proventriculitis, "nakanuke" and reticuloendotheliosis in chickens following vaccination with herpesvirus of turkeys (HVT) , 1977, Australian veterinary journal.

[16]  Y. Saito,et al.  Reticuloendotheliosis group virus pathogenic to chicken isolated from material infected with turkey herpesvirus (HVT). , 1976, Avian diseases.

[17]  T. Taniguchi,et al.  Isolation of a reticuloendotheliosis virus from chickens inoculated with Marek's disease vaccine. , 1976, National Institute of Animal Health quarterly.

[18]  S. Yamaguchi,et al.  Inoculation experiment of Marek's disease vaccine contaminated with a reticuloendotheliosis virus. , 1976, National Institute of Animal Health quarterly.

[19]  R. Huebner,et al.  AN AVIAN LEUCOSIS GROUP-SPECIFIC COMPLEMENT FIXATION REACTION. APPLICATION FOR THE DETECTION AND ASSAY OF NON-CYTOPATHOGENIC LEUCOSIS VIRUSES. , 1964, Virology.